Bio-Path Holdings Inc. (BPTH) Soars 6.92% on December 13

Bio-Path Holdings Inc. (BPTH) Soars 6.92% on December 13

Bio-Path Holdings Inc. (BPTH) had a good day on the market for Thursday December 13 as shares jumped 6.92% to close at $0.26. About 57,343 shares traded hands on 287 trades for the day, compared with an average daily volume of n/a shares out of a total float of 13.6 million. After opening the trading day at $0.26, shares of Bio-Path Holdings Inc. stayed within a range of $0.27 to $0.23.

With today’s gains, Bio-Path Holdings Inc. now has a market cap of $3.51 million. Shares of Bio-Path Holdings Inc. have been trading within a range of $3.09 and $0.21 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Bio-Path Holdings Inc is a US-based clinical and preclinical stage company. It focuses on oncology antisense drug development utilizing a novel technology. The company’s drug delivery and antisense technology referred as DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by enzymes when circulating in vivo, incorporated inside of a neutrally charged lipid bilayer. The lead drug candidate of the company is prexigebersen which is a nonproprietary drug for acute myeloid leukemia as well as solid tumors, including breast cancer and ovarian cancer. Its other drug candidate is Liposomal Bcl2 which targets the protein Bcl2, which is responsible for driving cell proliferation of all cancers.

Bio-Path Holdings Inc. is based out of Bellaire, TX and has some 9 employees. Its CEO is Peter H. Nielsen.

error: Content is protected !!